DUBLIN and SAN DIEGO – January 30, 2019 – Medtronic plc (NYSE:MDT) today announced new data supporting the long-term durability, safety, and efficacy of the Valiant(TM) Captivia(TM) thoracic stent graft system for the treatment of blunt thoracic aortic injury (BTAI). The presentation by Himanshu J. Patel, M.D., University of Michigan Department […]
Tag: Medtronic
Medtronic to Acquire EPIX Therapeutics, Expanding Its Cardiac Ablation Portfolio
DUBLIN – January 24, 2019 – Medtronic plc (NYSE: MDT) today announced that it has entered into a definitive agreement to acquire EPIX Therapeutics, Inc. (EPIX), a privately-held medical device company that designs and manufactures a novel, catheter-based, temperature-controlled cardiac ablation system for the treatment of patients with cardiac arrhythmias (irregular […]
Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB
DUBLIN and LEIPZIG, Germany – January 22, 2019 – Medtronic plc (NYSE:MDT) today announced new data shared on the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. Outcomes from the IN.PACT DCB Paclitaxel Safety Analysis, an independent, patient-level survival […]
Medtronic Launches Mobile App That Communicates Directly with World’s First Smartphone-Connected Pacemakers
DUBLIN – January 15, 2019 – Medtronic plc (NYSE:MDT) today announced the launch of its MyCareLink Heart(TM) mobile app to support the world’s first and only portfolio of pacemakers that can communicate directly with patients’ smartphones and tablets. Compatible with Medtronic BlueSync(TM) technology-enabled pacemakers, the MyCareLink Heart mobile app is designed […]
MEDTRONIC STATEMENT REGARDING RECENT DOJ ANNOUNCEMENT
DUBLIN – December 4, 2018 – Medtronic plc has agreed with the United States Department of Justice (DOJ) to resolve three claims against Covidien LP and ev3, Inc., now part of Medtronic. Regarding a matter concerning the Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry, […]
Medtronic Announces First Patient Treated in TERMINATE AF Clinical Trial
DUBLIN – December 3, 2018 – Medtronic plc (NYSE:MDT) today announced the first patient treated in the TERMINATE AF trial, a multi-center study evaluating two surgical ablation devices – the Cardioblate(TM) Irrigated RF (IRF) System and the CryoFlex(TM) Surgical Ablation System – for the treatment of non-paroxysmal (persistent or longstanding persistent) […]
Edwards Lifesciences and Medtronic Lead the U.S. TAVR Market, Despite Threat of New Competition – New Analysis from iData Research
VANCOUVER, British Columbia–(BUSINESS WIRE)–According to a new series of reports by iData Research, the United States cardiac surgery device market is valued at $5.7 billion USD and is forecast to exceed $10 billion by 2024. The largest segment of the cardiac surgery market is the transcatheter heart valve replacement (THVR) […]
MEDTRONIC REPORTS SECOND QUARTER FINANCIAL RESULTS
DUBLIN – November 20, 2018 – Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2019, which ended October 26, 2018. The company reported second quarter worldwide revenue of $7.481 billion, an increase of 6.1 percent as reported or 7.5 percent on an organic basis, […]
New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System
DUBLIN and NEW YORK – November 16, 2018 – Medtronic plc (NYSE:MDT) today announced new data on the Heli-FX(TM) EndoAnchor(TM) system, which demonstrated durability, safety and efficacy in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those with hostile aortic neck anatomies. The new data were unveiled in presentations at the […]
Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System
DUBLIN – November 13, 2018 – Medtronic plc (NYSE:MDT) today announced it has received CE Mark approval for the Valiant Navion(TM) thoracic stent graft system for the minimally invasive repair of all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), blunt traumatic aortic injuries (BTAI), penetrating atherosclerotic ulcers (PAU), […]



